Roelof Botha

Doug was on a call earlier today, actually.

We had a difficult conversation.

I wanted his input on an important question.

And it's not because he has the authority to tell me what to do.

It's because I seek out his advice.

So the business we invested in that has done really well is a company called Natera.

And we made a seed investment of a million dollars in 2007 in this company.

It's $20 billion now, right?

$22 billion market cap.

It was a million dollars, two people with a very raw idea.

And today they're the leading provider of prenatal testing, oncology, recurrence monitoring, organ transplant, rejection testing.

And so that company has been a huge success.

Diagnostics, genetic diagnostics, has been a huge success.

And you think about the dividend we're still collecting today.

from the Human Genome Project 25 years ago.

It's incredible.

And you've obviously seen that in some of the businesses that you've helped build as well.

We did make an investment in a company called BridgeBio, which is helping with rare genetic disease drug development.

But other than that, I think we just don't have the expertise for biotech.

You know, we don't have any... But there are still winners.